問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

曾堯麟

Recruiting

List

17Cases

2022-12-15 - 2027-12-31

Phase I/II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2024-09-01 - 2038-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2023-03-31 - 2030-12-30

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting1Sites

Recruiting4Sites

2020-09-22 - 2024-03-29

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting6Sites

Terminated1Sites

2024-04-01 - 2027-05-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2018-08-01 - 2026-12-01

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting8Sites

2019-05-01 - 2022-12-31

Phase II/III

A Randomized, Open-label, Controlled, Multi-Center Phase II/III Study to Assess the Efficacy and Safety of AZD3759 vs. a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (Erlotinib or Gefitinib), as First Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive Advanced Non-Small Cell Lung Cancer with Central Nervous System Metastasis

  • Condition/Disease

    Advanced Non-Small Cell Lung Cancer with Central Nervous System Metastasis

  • Test Drug

    AZD3759

Participate Sites
4Sites

Recruiting4Sites

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB